Molecular Partners today announced its Quarterly Management Statement for the period ending September 30, 2016 and key financial highlights for the third quarter 2016
Monthly Archives: October 2016
Abicipar Phase 2 Data in DME were presented at 2016 AAO Annual Meeting in Chicago which support progression to phase 3
Allergan to Present Abicipar Phase 2 Data of PALM Study in DME at AAO Annual Meeting
Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a powerful new class of therapies known as DARPin® therapies, announces additional details about its ongoing clinical oncology program MP0250.
Molecular Partners regained the rights to multi-DARPin® drug candidate